Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update
“We made considerable progress during the quarter despite the sustained headwinds of the COVID-19 pandemic, as we continued to advance our Phase 3 registration clinical trials addressing Acinetobacter infections and gonorrhea, further delivered on our pipeline, and strengthened our balance sheet from the closing of a
“In addition to our operational progress in the third quarter, we also presented at multiple investor conferences and were pleased to present four posters on SUL-DUR at the virtual IDWeek 2020 Conference, which included demonstration of its robust activity against global multidrug resistant Acinetobacter baumannii clinical isolates. We continue to be encouraged by our progress toward achieving our objectives and believe we are optimally positioned and well-funded as we conclude 2020 and look toward 2021.”
Third Quarter 2020 and Recent Highlights
- In August, the Company announced that it had entered into a
$25 millionprivate placement agreement with two healthcare investors. The Company intends to use the net proceeds for the continued support of the ongoing ATTACK Phase 3 registration clinical trial as well as for working capital and other general corporate purposes. ATTACK is a global Phase 3 registration trial evaluating SUL-DUR for the treatment of patients with pneumonia and bloodstream infections caused by Acinetobacter baumannii, including carbapenem-resistant strains.
- In September, the Company presented virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference, the Cantor 2020 Virtual Global Healthcare Conference, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. In August, the Company presented at the 2020 Wedbush PacGrow Healthcare Virtual Conference and at the Canaccord Genuity 40th Annual Growth Conference.
- The Company continues with enrollment of the ATTACK Phase 3 registration clinical trial in 17 countries, and to-date has had two pre-planned Data and Safety Monitoring Board reviews, including one most recently in
July 2020. Although the Company remains blinded to the data, both reviews recommended continuation of the trial without protocol modification. While not providing specific guidance on the timing of top-line data from ATTACK due to the unpredictability of the COVID-19 pandemic, the Company remains in close contact with its contract research organization to optimize the allocation of its resources and funded activities in an effort to mitigate the impact on its trial sites and anticipated timeline.
- During the virtual IDWeek 2020 held on
October 21-25, the company presented four posters highlighting SUL-DUR’s potential. Two posters detailed findings demonstrating activity of SUL-DUR against multidrug-resistant Acinetobacter clinical isolates from the Middle Eastas well as global Acinetobacter baumannii-calcoaceticus complex clinical isolates. In addition, a retrospective review of serious infections caused by carbapenem-susceptible and carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex was presented, which concluded that such infections are associated with high mortality rates and that carbapenem resistance appears to be a contributing factor. Lastly, the Company highlighted the in vitro intrinsic microbiological activity of durlobactam and combinations against multidrug resistant Mycobacterium abscessus.
- With patient enrollment and other trial activities resuming in
July 2020, the Company is continuing to support the Phase 3 registration clinical trial of zoliflodacin for the treatment of uncomplicated gonorrhea with the Global Antibiotic Research and Development Partnership(GARDP). The trial plans to enroll patients with uncomplicated gonorrhea, including infections caused by multidrug resistant strains of N. gonorrhoeae, at 14 clinical trial sites across the United States, Netherlands, South Africaand Thailand, and will assess the safety and efficacy of oral zoliflodacin versus the combination of intramuscular ceftriaxone plus oral azithromycin, the current standard of care. While not providing specific guidance on the timing of top-line data from this trial due to the unpredictability of the COVID-19 pandemic, the Company and GARDP are working to optimize the allocation of their resources and funded activities in an effort to mitigate the impact on their trial sites and anticipated timeline.
- In August, the Company co-authored a review of recent progress in adapting non-clinical models to facilitate research and development of new agents for treating gonorrhea, based on the
November 2019expert workshop organized by the Global Antibiotic Research and Development Partnership(GARDP). The review was featured in the peer-reviewed journal, Clinical Microbiology and Infection.
- In October, the Company presented at the Boston Area Antimicrobial Resistance Network (BAARN) Meeting 2020 an oral presentation titled, “Antibacterial Drug Discovery: Competing Methyl Efforts on Biochemical Potency and Cell Accumulation.”
Third Quarter 2020 Financial Results
The Company reported a net loss of
Research and development expenses were
General and administrative expenses were
Based on our current operating plan, we believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2021.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.
Entasis Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis’ collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Many of these factors are beyond Entasis’ control. These and other risks and uncertainties are described more fully in the Entasis’ filings with the
(Financial Tables Follow)
|Condensed Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
|Three Months Ended
||Nine Months Ended
|Research and development||9,387||7,606||31,249||29,286|
|General and administrative||3,213||3,521||10,235||10,130|
|Total operating expenses||12,600||11,127||41,484||39,416|
|Loss from operations||(12,600||)||(4,127||)||(41,484||)||(32,416||)|
|Total other income||1,467||966||1,689||3,075|
|Loss before income taxes||(11,133||)||(3,161||)||(39,795||)||(29,341||)|
|Provision for income taxes||-||324||-||467|
|Net loss per share—basic and diluted||$||(0.37||)||$||(0.27||)||$||(1.97||)||$||(2.27||)|
|Weighted average common stock outstanding—basic and diluted||29,960,219||13,134,538||20,151,570||13,130,837|
|Condensed Consolidated Balance Sheets|
|Cash, cash equivalents and investments||$||61,190||$||40,996|
|Total stockholders' equity||62,236||42,157|
|Total liabilities and stockholders’ equity||$||69,962||$||51,034|
Source: Entasis Therapeutics Holdings Inc.